Nomogram-derived scores stratified patients into prognostically distinct subgroups with significant differences in OS and RFS.<h4>Conclusions</h4>This study established internally validated 3-year OS and RFS nomograms for pediatric <i>RUNX1::RUNX1T1</i>-positive AML with excellent discrimination and clinical utility. This evidence concerns the gene RUNX1 and acute myeloid leukemia.